DZ3484A1 - Compositions pharmaceutiques comprenant un agoniste des recepteurs nmda - Google Patents

Compositions pharmaceutiques comprenant un agoniste des recepteurs nmda

Info

Publication number: DZ3484A1
Authority: DZ; Algeria
Prior art keywords: pharmaceutical compositions; receptor agonist; nmda receptor; nmda; agonist
Prior art date: 2000-12-13

Application number

DZ013484A

Other languages

English (en)

Inventor

Jinyang Hong

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-13

Filing date

2001-12-05

Publication date

2002-06-20

2001-12-05 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2002-06-20 Application granted granted Critical

2002-06-20 Publication of DZ3484A1 publication Critical patent/DZ3484A1/fr

Links

239000003706 n methyl dextro aspartic acid receptor stimulating agent Substances 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Psychology (AREA)
Inorganic Chemistry (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Addiction (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DZ013484A 2000-12-13 2001-12-05 Compositions pharmaceutiques comprenant un agoniste des recepteurs nmda DZ3484A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US25537200P	2000-12-13	2000-12-13
PCT/IB2001/002359 WO2002047685A2 (fr)	2000-12-13	2001-12-05	Compositions pharmaceutiques de l'agoniste du recepteur nmda

Publications (1)

Publication Number	Publication Date
DZ3484A1 true DZ3484A1 (fr)	2002-06-20

Family

ID=22968017

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DZ013484A DZ3484A1 (fr)	2000-12-13	2001-12-05	Compositions pharmaceutiques comprenant un agoniste des recepteurs nmda

Country Status (41)

Country	Link
US (2)	US6635270B2 (fr)
EP (1)	EP1347760B1 (fr)
JP (1)	JP2004515529A (fr)
KR (1)	KR100533407B1 (fr)
CN (1)	CN1273135C (fr)
AP (1)	AP1235A (fr)
AR (1)	AR035607A1 (fr)
AT (1)	ATE296629T1 (fr)
AU (2)	AU2002218454B2 (fr)
BG (1)	BG107788A (fr)
BR (1)	BR0116085A (fr)
CA (1)	CA2431172A1 (fr)
CZ (1)	CZ20031543A3 (fr)
DE (1)	DE60111265T2 (fr)
DO (1)	DOP2001000300A (fr)
DZ (1)	DZ3484A1 (fr)
EA (1)	EA006489B1 (fr)
EC (1)	ECSP034655A (fr)
EE (1)	EE200300284A (fr)
ES (1)	ES2239648T3 (fr)
GE (1)	GEP20053568B (fr)
HR (1)	HRP20030473A2 (fr)
HU (1)	HUP0400645A2 (fr)
IL (1)	IL155810A0 (fr)
IS (1)	IS6811A (fr)
MA (1)	MA26970A1 (fr)
MX (1)	MXPA03005257A (fr)
NO (1)	NO20032678L (fr)
NZ (1)	NZ525742A (fr)
OA (1)	OA12414A (fr)
PA (1)	PA8534901A1 (fr)
PE (1)	PE20020710A1 (fr)
PL (1)	PL362080A1 (fr)
PT (1)	PT1347760E (fr)
SK (1)	SK6982003A3 (fr)
TN (1)	TNSN01173A1 (fr)
UA (1)	UA73619C2 (fr)
UY (1)	UY27068A1 (fr)
WO (1)	WO2002047685A2 (fr)
YU (1)	YU41103A (fr)
ZA (1)	ZA200303892B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL2368554T3 (pl)	2003-04-08	2015-05-29	Progenics Pharm Inc	Preparaty farmaceutyczne zawierające metylonaltrekson
TW200800959A (en) *	2005-06-10	2008-01-01	Wyeth Corp	Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
TW200808740A (en) *	2006-06-09	2008-02-16	Wyeth Corp	Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof
TW200811144A (en) *	2006-06-09	2008-03-01	Wyeth Corp	Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline
TW200808741A (en) *	2006-06-09	2008-02-16	Wyeth Corp	6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts
TWI489984B (zh)	2006-08-04	2015-07-01	Wyeth Corp	用於非經腸道傳輸化合物之配方及其用途
TW200831096A (en) *	2006-11-28	2008-08-01	Wyeth Corp	Metabolites of 5-Fluoro-8-{4-[4-(6-methoxyquinolin-8-yl)piperazin-1-yl]piperidin-1-yl} quinoline and methods of preparation and uses thereof
TW200901974A (en)	2007-01-16	2009-01-16	Wyeth Corp	Compounds, compositions, and methods of making and using them
CN101317844B (zh) *	2007-06-08	2010-11-17	章劲夫	化合物(+)-5-甲基-10，11-二氢-5H-二苯并〔a，d〕环庚烯-5，10-亚胺在制备避孕药物中的应用
MX2011003015A (es)	2008-09-18	2011-11-18	Univ Northwestern	Moduladores del receptor de n-metil-d-aspartato, y usos de los mismos.
US8951968B2 (en)	2009-10-05	2015-02-10	Northwestern University	Methods of treating depression and other related diseases
SG10201501050RA (en)	2010-02-11	2015-04-29	Univ Northwestern	Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof
KR101692275B1 (ko)	2010-02-11	2017-01-04	노오쓰웨스턴 유니버시티	２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
CN102586243A (zh) *	2012-03-08	2012-07-18	中国人民解放军军事医学科学院放射与辐射医学研究所	一种预防电磁辐射致脑损伤的标志物
US10154988B2 (en)	2012-11-14	2018-12-18	The Johns Hopkins University	Methods and compositions for treating schizophrenia
CN105308049A (zh)	2013-01-29	2016-02-03	阿普廷伊克斯股份有限公司	螺-内酰胺nmda受体调节剂及其用途
SG11201505937SA (en)	2013-01-29	2015-09-29	Naurex Inc	Spiro-lactam nmda receptor modulators and uses thereof
WO2014120784A1 (fr)	2013-01-29	2014-08-07	Naurex, Inc.	Modulateurs spirolactames d'un récepteur nmda et leurs utilisations
JP6419087B2 (ja)	2013-01-29	2018-11-07	アプティニックスインコーポレイテッド	スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
CA2898861C (fr)	2013-01-29	2021-07-20	Naurex, Inc.	Modulateurs spirolactames d'un recepteur nmda et leurs utilisations
EP3087987A4 (fr)	2013-12-23	2017-08-02	Samyang Biopharmaceuticals Corporation	Composition pharmaceutique contenant du palonosétron
PE20190174A1 (es)	2016-05-19	2019-02-01	Aptinyx Inc	Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos
WO2017201285A1 (fr)	2016-05-19	2017-11-23	Aptinyx Inc.	Modulateurs spirolactames des récepteurs nmda et leurs utilisations
CN109890825B (zh)	2016-08-01	2022-03-11	阿普廷伊克斯股份有限公司	螺-内酰胺nmda受体调节剂及其用途
CA3031534C (fr)	2016-08-01	2023-10-17	Aptinyx Inc.	Modulateurs spiro-lactames des recepteurs nmda et leurs utilisations
PE20190501A1 (es)	2016-08-01	2019-04-10	Aptinyx Inc	Moduladores nmda espiro-lactam y metodos de uso de los mismos
EP3490992B1 (fr)	2016-08-01	2023-03-22	Aptinyx Inc.	Modulateurs spiro-lactames des récepteurs nmda et leurs utilisations
JP2019527235A (ja)	2016-08-01	2019-09-26	アプティニックスインコーポレイテッド	スピロ−ラクタム及びビス−スピロ−ラクタムｎｍｄａ受容体修飾因子及びその使用
PE20210455A1 (es)	2018-01-31	2021-03-08	Aptinyx Inc	Moduladores del receptor nmda espiro-lactama y usos de los mismos
US12012413B2 (en)	2019-11-11	2024-06-18	Tenacia Biotechnology (Hong Kong) Co., Limited	Methods of treating painful diabetic peripheral neuropathy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5272160A (en) *	1989-05-17	1993-12-21	Pfizer Inc	2-piperidino-1-alkanol derivatives as antiischemic agents
US5710168A (en) *	1991-10-23	1998-01-20	Pfizer Inc.	2-piperidino-1-alkanol derivatives as neuroprotective agents
IL122649A (en) *	1995-08-11	2001-08-26	Pfizer	(1s, 2s) - 1- (4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol methanesulfonate trihydrate, its use in the preparation of medicaments and pharmaceutical compositions comprising same
TW450807B (en) *	1995-09-15	2001-08-21	Pfizer	Pharmaceutical compositions for treating tinnitus comprising neuroprotective agents

2001
- 2001-05-12 UA UA2003065485A patent/UA73619C2/uk unknown
- 2001-12-05 NZ NZ525742A patent/NZ525742A/en unknown
- 2001-12-05 EP EP01270205A patent/EP1347760B1/fr not_active Expired - Lifetime
- 2001-12-05 ES ES01270205T patent/ES2239648T3/es not_active Expired - Lifetime
- 2001-12-05 MX MXPA03005257A patent/MXPA03005257A/es active IP Right Grant
- 2001-12-05 KR KR10-2003-7007874A patent/KR100533407B1/ko not_active Expired - Fee Related
- 2001-12-05 IL IL15581001A patent/IL155810A0/xx unknown
- 2001-12-05 AU AU2002218454A patent/AU2002218454B2/en not_active Ceased
- 2001-12-05 HR HR20030473A patent/HRP20030473A2/hr not_active Application Discontinuation
- 2001-12-05 DE DE60111265T patent/DE60111265T2/de not_active Expired - Fee Related
- 2001-12-05 AT AT01270205T patent/ATE296629T1/de not_active IP Right Cessation
- 2001-12-05 CN CNB018203922A patent/CN1273135C/zh not_active Expired - Fee Related
- 2001-12-05 BR BR0116085-0A patent/BR0116085A/pt not_active IP Right Cessation
- 2001-12-05 GE GE5171A patent/GEP20053568B/en unknown
- 2001-12-05 US US10/010,827 patent/US6635270B2/en not_active Expired - Fee Related
- 2001-12-05 CZ CZ20031543A patent/CZ20031543A3/cs unknown
- 2001-12-05 DZ DZ013484A patent/DZ3484A1/fr active
- 2001-12-05 CA CA002431172A patent/CA2431172A1/fr not_active Abandoned
- 2001-12-05 YU YU41103A patent/YU41103A/sh unknown
- 2001-12-05 JP JP2002549256A patent/JP2004515529A/ja active Pending
- 2001-12-05 OA OA1200300145A patent/OA12414A/en unknown
- 2001-12-05 HU HU0400645A patent/HUP0400645A2/hu unknown
- 2001-12-05 SK SK698-2003A patent/SK6982003A3/sk unknown
- 2001-12-05 AU AU1845402A patent/AU1845402A/xx active Pending
- 2001-12-05 WO PCT/IB2001/002359 patent/WO2002047685A2/fr not_active Ceased
- 2001-12-05 PT PT01270205T patent/PT1347760E/pt unknown
- 2001-12-05 EE EEP200300284A patent/EE200300284A/xx unknown
- 2001-12-05 PL PL01362080A patent/PL362080A1/xx not_active Application Discontinuation
- 2001-12-05 EA EA200300514A patent/EA006489B1/ru not_active IP Right Cessation
- 2001-12-10 DO DO2001000300A patent/DOP2001000300A/es unknown
- 2001-12-11 AR ARP010105748A patent/AR035607A1/es unknown
- 2001-12-11 PE PE2001001235A patent/PE20020710A1/es not_active Application Discontinuation
- 2001-12-12 UY UY27068A patent/UY27068A1/es not_active Application Discontinuation
- 2001-12-12 TN TNTNSN01173A patent/TNSN01173A1/fr unknown
- 2001-12-13 PA PA20018534901A patent/PA8534901A1/es unknown
- 2001-12-13 AP APAP/P/2001/002376A patent/AP1235A/en active
2003
- 2003-05-08 IS IS6811A patent/IS6811A/is unknown
- 2003-05-09 BG BG107788A patent/BG107788A/bg unknown
- 2003-05-20 ZA ZA200303892A patent/ZA200303892B/en unknown
- 2003-06-03 MA MA27191A patent/MA26970A1/fr unknown
- 2003-06-12 NO NO20032678A patent/NO20032678L/no not_active Application Discontinuation
- 2003-06-13 EC EC2003004655A patent/ECSP034655A/es unknown
- 2003-08-19 US US10/643,441 patent/US20040039022A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ATE296629T1 (de)	2005-06-15
EA006489B1 (ru)	2005-12-29
CN1479617A (zh)	2004-03-03
KR100533407B1 (ko)	2005-12-02
UY27068A1 (es)	2002-07-31
BG107788A (bg)	2004-01-30
HRP20030473A2 (en)	2005-04-30
YU41103A (sh)	2006-05-25
TNSN01173A1 (fr)	2005-11-10
EE200300284A (et)	2003-10-15
ZA200303892B (en)	2004-05-20
OA12414A (en)	2006-04-18
BR0116085A (pt)	2003-12-23
NO20032678D0 (no)	2003-06-12
AU2002218454B2 (en)	2005-10-27
IS6811A (is)	2003-05-08
NZ525742A (en)	2005-07-29
PA8534901A1 (es)	2002-08-26
CZ20031543A3 (cs)	2004-06-16
IL155810A0 (en)	2003-12-23
NO20032678L (no)	2003-06-12
DE60111265T2 (de)	2006-05-04
US20040039022A1 (en)	2004-02-26
DOP2001000300A (es)	2002-05-30
UA73619C2 (en)	2005-08-15
AP1235A (en)	2004-01-06
HK1059575A1 (en)	2004-07-09
PL362080A1 (en)	2004-10-18
US6635270B2 (en)	2003-10-21
US20020111366A1 (en)	2002-08-15
EP1347760A2 (fr)	2003-10-01
EP1347760B1 (fr)	2005-06-01
CN1273135C (zh)	2006-09-06
AU1845402A (en)	2002-06-24
AR035607A1 (es)	2004-06-16
GEP20053568B (en)	2005-07-11
MA26970A1 (fr)	2004-12-20
CA2431172A1 (fr)	2002-06-20
EA200300514A1 (ru)	2003-10-30
PT1347760E (pt)	2005-09-30
PE20020710A1 (es)	2002-08-09
KR20030070060A (ko)	2003-08-27
DE60111265D1 (de)	2005-07-07
HUP0400645A2 (hu)	2004-06-28
ECSP034655A (es)	2003-07-25
WO2002047685A2 (fr)	2002-06-20
WO2002047685A3 (fr)	2002-08-15
MXPA03005257A (es)	2003-09-25
JP2004515529A (ja)	2004-05-27
AP2001002376A0 (en)	2001-12-31
ES2239648T3 (es)	2005-10-01
SK6982003A3 (en)	2004-08-03

Publication	Publication Date	Title
NO20032678L (no)	2003-06-12	NMDA reseptor agonist farmasöytiske sammensetninger
FR2804025B1 (fr)	2002-08-23	Compositions pharmaceutiques stabilisees
NO20023728D0 (no)	2002-08-07	Manipuleringsresistente, orale opioidagonistformuleringer
ITTO20010005A1 (it)	2001-07-11	Formulazione farmaceutica.
EP1390034A4 (fr)	2005-07-13	Antagonistes de nmda/nr2b nonaryl-heterocyclo amidyle n-substitues
PL365377A1 (en)	2005-01-10	Amide derivatives as nmda receptor antagonists
HUP0301777A3 (en)	2010-09-28	Aniline-derived ligands for the thyroid receptor, pharmaceutical compositions comprising thereof and their use
CY2011013I1 (el)	2014-04-09	Στερεες φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν εναν αγωνιστη υποδοχεα s1p και μια αλκοολη σακχαρων
CY2007031I2 (el)	2009-11-04	Συνθεση στοματικης δοσολογιας παρατεταμενης απελευθερωσης
EG24194A (en)	2008-10-14	5ht-a-partial agonist pharmaceutical compositions
DE60122495D1 (de)	2006-10-05	TRANS-N-i4-(4-HYDROXYPHENYL)CYCLOHEXYLö-3-PHENYLPROPIONAMID ALS SUBTYP-SELEKTIVER NMDA REZEPTOR ANTAGONIST
DK1068202T3 (da)	2009-03-16	1-(-heteroarylpropyl- eller -prop-2-enyl)-4benzylpipderidiner som NMDA-receptor-antagonister
IL161997A0 (en)	2005-11-20	Pharmaceutical composition comprising a 5ht1 receptor agonist
FR2802423B1 (fr)	2005-03-25	Compositions pharmaceutiques
FR2792529B1 (fr)	2001-09-28	Nouvelles compositions pharmaceutiques comprenant des derives de 2-isoxazole-8-aminotetralines
AU2001286409A1 (en)	2002-02-18	N-methyl-d-aspartate receptor antagonists
FR2797444B1 (fr)	2003-02-07	Compositions pharmaceutiques comprenant des 4-quinolones
MA26604A1 (fr)	2004-12-20	Compositions pharmaceutiques.
NO20032957D0 (no)	2003-06-26	Farmasöytisk emulsjonspreparat
HUP0200057A3 (en)	2004-03-29	Dopamine d1 receptor agonist compounds, pharmaceutical compositions containing them and their use
SI1347760T1 (en)	2005-10-31	Nmda receptor agonist pharmaceutical compositions
DK1200400T3 (da)	2004-12-27	Substituerede pyrrolidin-2,3,4-trion derivater, der er anvendelse som NMDA-receptorantagonister
DK1450770T3 (da)	2005-08-01	Farmaceutisk præparat, der omfatter en 5HT1-receptoragonist
SE9901967D0 (sv)	1999-05-31	New solid dosage formulation
ES1049514Y (es)	2002-04-16	Dispensador dosificador para sustancias higienicas.